Abstract:
A composition for inhibiting breast cancer comprising jaceosidin is provided to treat breast cancer without toxicity to breast cells by inhibiting activity, infiltration and mobility of matrix metalloproteinase(MMP). The composition for inhibiting breast cancer comprises jaceosidin(5,7,4'-tetramethoxy 6,3'-dimethoxyflavone) represented by the formula(1) as an effective ingredient, wherein the effective concentration of jaceosidin is 10-50 mu M. The composition is the pharmaceutical or food composition.
Abstract:
본 발명은 셀레노시스테인 또는 셀레노메타이오닌을 포함하는 갭 결합을 통한 세포간 정보전달 억제 예방 및 치료용 조성물에 관한 것이다. 특히 본 발명은 갭 결합을 통한 세포간 정보전달 억제를 방지 및 회복시키며 동시에 세포에 무해한 셀레노시스테인 및 셀레노메타이오닌으로 이루어진 군에서 선택되는 적어도 하나의 셀레노아미노산을 유효성분으로 포함하는 조성물을 제공하며, 상기 조성물은 갭 결합을 통한 세포간 정보전달의 불균형에 의해 발생되는 질환의 예방 및 치료제 용도로 적용할 수 있을 뿐만 아니라, 기존의 약제에 병용사용함으로써 약제의 약리효과를 향상시킬 수 있다. 셀레노시스테인, 셀레노메타이오닌, 갭 결합을 통한 세포간 정보전달
Abstract:
본 발명은 허수테논(hirsutenone)을 포함하는 건강 증진용 식품에 관한 것으로, 본 발명에 따른 조성물은 매트릭스 메탈로프로티나아제 (Matrix metalloproteinase : MMP)의 활성을 저해함으로써 간암의 진행과 전이를 억제하는데 유용하게 사용될 수 있으며, 이러한 목적을 갖는 약제, 가공 식품, 기능성 식품, 음료 및 주류의 제조에도 이용될 수 있다.
Abstract:
본 발명은 독소루비신(DOXORUBICIN) 및 코코아 추출물을 포함하는 항암 조성물에 관한 것이다. 특히 본 발명의 항암 조성물은 독소루비신의 부작용인 갭 결합을 통한 세포간 신호 전달의 억제를 회복시키므로써 독소루비신의 부작용을 보완할 수 있으며, 간암세포의 전이에 주요하게 관여하는 매트릭스 메탈로프로티나아제(Matrix metalloproteinase: MMP)의 활성 억제 효과를 증강시켜 효율적으로 간암을 억제할 수 있을 뿐만 아니라, 이를 약제, 식품, 음료 및 주류로 활용가능하다.
Abstract:
PURPOSE: Provided is a composition for preventing and treating disease associated with inhibition of gap junctional internal cellular communication and unbalance of Homeostasis, which composition contains Ulmus macrocarpa HANCE extract and effectively recovers the inhibition of gap junctional internal cellular communication and the unbalance of Homeostasis. It is therefore, used for manufacture of medicaments, processed foods, functional foods, beverages and drinks. CONSTITUTION: A composition for preventing and treating disease associated with inhibition of gap junctional internal cellular communication and unbalance of Homeostasis is characterized by containing, as an active ingredient, an effective amount of Ulmus macrocarpa HANCE extract or its active fraction, and pharmaceutically acceptable carriers. The extract is obtained by extracting Ulmus macrocarpa HANCE with 60% ethanol solution or hot water.
Abstract:
PURPOSE: Provided is a composition for preventing and treating disease associated with inhibition of gap junctional internal cellular communication and unbalance of Homeostasis, which composition contains Abies nephrolepis leaf extract and effectively recovers the inhibition of gap junctional internal cellular communication and the unbalance of Homeostasis. It is therefore, used for manufacture of medicaments, processed foods, functional foods, beverages and drinks. CONSTITUTION: A composition for preventing and treating disease associated with inhibition of gap junctional internal cellular communication and unbalance of Homeostasis is characterized by containing, as an active ingredient, an effective amount of Abies nephrolepis leaf extract, and pharmaceutically acceptable carriers. The extract is obtained by extracting Abies nephrolepis leaf at 80-90 deg.C for 2-3 hours with 60% ethanol solution.
Abstract:
A MEK1(mitogen-activated protein kinase kinase 1) inhibitor containing RSVL2(3,5,3',4',5'-pentahydroxy-trans-stilbene) is provided to selectively inhibit MEK1 and AP-1(activator protein 1) and treat various inflammatory diseases. A MEK1 inhibitor comprises a RSVL2(3,5,3',4',5'-pentahydroxy-trans-stilbene) of the chemical formula 1 as an active ingredient. A pharmaceutical composition for preventing and treating inflammatory disease comprises 0.01-50 weight% of RSVL2. A pharmaceutical composition further comprises a pharmaceutically allowable carrier, diluents, or excipient. The daily dose of the composition is 0.1-100 mg/kg(weight). A food composition for preventing inflammatory disease comprises 0.001-50 weight% of RSVL2.
Abstract:
An anticancer composition containing a 5-deoxykaempferol is provided to inhibit the activation of matrix metalloproteinase(MMP) and the infiltration of cancer cell. An anticancer composition of 0.1-50 weight% of 5-deoxykaempferol of the chemical formula 1 an active ingredient. The anticancer comprise medicine, food, food additive, beverage, or beverage additive. The cancer is colon cancer, stomach cancer, breast cancer, and liver cancer. The anticancer composition further comprises a pharmaceutically allowable carrier, diluents, or excipient. The daily dose of anticancer composition is 0.1-100 mg/kg(body weight).